Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,500 shares of the biotechnology company’s stock after acquiring an additional 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Sarepta Therapeutics were worth $3,222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter worth approximately $36,000. Finally, Values First Advisors Inc. purchased a new position in Sarepta Therapeutics during the third quarter worth approximately $59,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Evercore ISI reduced their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. HC Wainwright restated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $176.77.

Sarepta Therapeutics Trading Down 0.3 %

SRPT opened at $109.46 on Friday. Sarepta Therapeutics, Inc. has a 12 month low of $102.15 and a 12 month high of $173.25. The stock has a market capitalization of $10.46 billion, a price-to-earnings ratio of 87.57 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business has a fifty day moving average price of $119.82 and a 200 day moving average price of $125.11.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.